identified the adenosine A2A receptor agonist and PPARδ agonist GW0742 as potential therapeutic targets for autism by decreasing the levels of IL‐17A, RORγt, Stat3, and pStat3 and increasing the protein and mRNA expression of Foxp3 and IL‐10 (Ahmad et al., 2018; Ansari et al., 2017). This evidence concerns the gene FOXP3 and autism.